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Introduction
Porcine reproductive and respiratory syndrome (PRRS) is charac-
terized by reproductive failure in pregnant sows and respiratory 
distress in piglets and growing pigs, being considered one of the 
most important viral diseases of pigs in countries with extensive 
swine industry (Neumann et al., 2005). The disease is caused by 
PRRS virus (PRRSV), which was first isolated in Europe and then 
in the US (Collins et al., 1992). PRRSV is a single stranded RNA vi-
rus belonging to the family Arteriviridae, genus Arterivirus (Meu-
lenberg, 2000). Two distinct serotypes of PRRV are recognized, 
type I (European) and type II (US), both exhibiting a significant 
degree of genetic and antigenic heterogeneity while maintain-
ing identical pathobiological phenotypes (Snijder and Meulen-
berg, 2001). The viral genome is approximately 15.0 kb in length 
and contains nine open reading frames flanked by untranslated 
regions (UTRs) at the 5′- and 3′-end (Meulenberg, 2000). ORFs 1a 
and 1b encode for non-structural polypeptides with replicase-as-
sociated activities whereas ORFs 2–7 are translated from a nested 
set of subgenomic RNA (sgRNA) encoding the structural proteins 
(Snijder and Meulenberg, 2001). The major structural proteins in-
clude glycoprotein 5 (GP5), M and N (encoded by ORFs 5, 6 and 
7) while the minor structural proteins include GP2, GP3 and GP4 
(encoded by ORFs 2a, 3 and 4 respectively) and the small E pro-
tein (encoded by ORF 2b) (Snijder and Meulenberg, 2001; Wu 
et al., 2005). Analyses of purified virions of European strains of 
PRRSV have confirmed that six of these PRRSV proteins are au-
thentic structural proteins, these are: the four glycoproteins: GP2a, 
GP3, GP4 and GP5; a nonglycosylated membrane protein M and 
the nucleocapsid protein N (Dea et al., 2000). On the other hand, 
recent findings have demonstrated that 2b protein, expressed 
from a second ORF entirely contained within ORF2, is also a mi-
nor structural component of PRRSV (Wu et al., 2001, 2005). The 
structural nature of GP3 is still controversial, as there is conflicting 
data regarding its presence as a constituent of the envelope of vi-
rus particles. It has been convincingly demonstrated that GP3 is a 
45- to 50-kDa structural protein of the PRRSV LV (type I or Euro-
pean) strain (Meulenberg et al., 1995). However, the GP3 has been 
reported as being a non-structural protein of the PRRSV type II 
IAF-Klop strain, with a subset of viral GP3 being released into the 
cell culture medium as a non-virion associated and membrane-
free form (Gonin et al., 1998; Mardassi et al., 1998). In this context, 
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Abstract
Glycoprotein 3 (GP3) is a highly glycosylated PRRSV envelope protein which has been reported as being present in the vi-
rions of PRRSV type I, while missing in the type II PRRSV (US) virions. We herein present evidence that GP3 is indeed in-
corporated in the virus particles of a North American strain of PRRSV (FL12), at a density that is consistent with the minor 
structural role assigned to GP3 in members of the Arterivirus genus. Two 15aa peptides corresponding to two different im-
munodominant linear epitopes of GP3 derived from the North American strain of PRRSV (FL12) were used as antigen to 
generate a rabbit monospecific antiserum to this protein. The specificity of this anti-GP3 antiserum was confirmed by ra-
dioimmunoprecipitation (RIP) assay using BHK-21 cells transfected with GP3 expressing plasmid, MARC-145 cells infected 
with FL12 PRRSV, as well as by confocal microscopy on PRRSV-infected MARC-145 cells. To test if GP3 is a structural com-
ponent of the virion, 35S-labelled PRRSV virions were pelleted through a 30% sucrose cushion, followed by a second round 
of purification on a sucrose gradient (20–60%). Virions were detected in specific gradient fractions by radioactive counts and 
further confirmed by viral infectivity assay in MARC 145 cells. The GP3 was detected in gradient fractions containing puri-
fied virions by RIP using anti-GP3 antiserum. Predictably, the GP3 was less abundant in purified virions than other major 
structural envelope proteins such as GP5 and M. Further evidence of the presence of GP3 at the level of PRRSV FL12 enve-
lope was obtained by immunogold staining of purified virions from the supernatant of infected cells with anti-GP3 antise-
rum. Taken together, these results indicate that GP3 is a minor structural component of the PRRSV type II (FL12 strain) vi-
rion, as had been previously described for PRRSV type I.
Keywords: GP3, PRRSV, sucrose gradient, structural protein, purified virions
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the observed in vivo immunogenicity of GP3 has been explained 
by its ability to be secreted from infected cells as previously de-
scribed (Mardassi et al., 1998). However, a structural role for GP3 
in PRRSV type II has been suggested by recent findings report-
ing its ability to induce neutralizing antibodies (Cancel-Tirado et 
al., 2004; Jiang et al., 2008). In addition, partial protective immu-
nity was observed in vivo by immunization of animals with a re-
combinant baculovirus expressing ORF3 (Plana Duran et al., 1997) 
or with recombinant fowlpox expressing GP3/GP5 (Shen et al., 
2007). Overall, it is evident that according to the available data, 
the structural nature of the GP3 in PRRSV type II virions is still 
unclear and remains a matter of controversy.
Glycoprotein 3 is the second most heterogeneous protein of 
PRRSV with approximately 54 to 60% amino acid identity between 
North American and European isolates (Meng et al., 1995). The pro-
tein encoded by ORF3 is also the most glycosylated PRRSV pro-
tein with seven putative N-linked glycosylation sites that are well 
conserved among strains from both PRRSV serotypes (Gonin et al., 
1998). Thus, the predicted molecular mass (Mr) of the ORF3 protein 
(27–29 kDa) is smaller than its apparent Mr estimated by gel electro-
phoresis (42–50 kDa) (Dea et al., 2000; Gonin et al., 1998).
We herein present evidence that GP3 is incorporated into virus 
particles of a North American strain of PRRSV (vFL12). Our re-
sults indicate that GP3 represents just a small fraction of the struc-
tural proteins of PRRSV, which is consistent with the notion that 
GP3 is one of the minor structural glycoproteins of the Arteriviri-
dae (Meulenberg, 2000; Snijder and Meulenberg, 2001).
Results
Generation and characterization of GP3 monospecific antiserum
In order to confirm the identity of GP3, we prepared an anti-GP3 
monospecific antiserum by injecting rabbits with two synthetic 
peptides conjugated to KLH. Both 15 amino acid peptides within 
ORF3 protein (Q61AAAEVYEPGRSLWC75 and S83EDDHDDLG-
FMVPG96C) were shown to be highly immunogenic in our previ-
ous experiment as measured by its reactivity with serum from pigs 
experimentally infected with a North American strain of PRRSV 
(de Lima et al., 2006). An emulsion containing both KLH-conju-
gated peptides emulsified in Freund’s adjuvant were injected in 
two rabbits at 2 weeks intervals. Specific anti-GP3 antiserum was 
collected at 77 days after the first injection, further characterized 
and used in all experiments. Specificity of the anti-GP3 antiserum 
was further confirmed by an indirect immunofluorescence stain-
ing of MARC 145 cells at about 48 h post infection with a PRRSV 
FL12 strain. A cytoplasmic pattern of staining was observed when 
the anti-GP3 antiserum was used as a primary antibody followed 
by a secondary anti-rabbit IgG antibody conjugated with Alexa 
Fluor 488 and observed under confocal microscopy with nuclei 
stained with DAPI (data not shown). No staining was observed 
following incubation of PRRSV-infected MARC-145 cells with rab-
bit pre-immune serum (data not shown).
The specificity of the anti-GP3 monospecific antiserum was 
further investigated by radioimmunoprecipitation assays. The 
gene encoding for GP3 protein of FL12 strain of PRRSV was PCR 
amplified and cloned into pGEM3 expression vector using EcoRI 
and XhoI restriction sites. The entire coding region was confirmed 
by nucleotide sequencing. Transfection followed by radioimmu-
noprecipitation using GP3 antibody revealed a clear protein spe-
cies of ~ 42–45 kDa (Figure 1A, lane 2). This particular signal was 
absent in the control lane which was processed in a similar way, 
but in this case transfected with pGEM3 only. This data clearly 
indicates specific reactivity of generated GP3 antibody against 
PRRSV GP3 protein. In addition the anti-GP3 monospecific an-
tiserum efficiently immunoprecipitated the GP3 from lysates of 
PRRSV-infected MARC-145 cells (Figure 1B, lane 2). In the same 
experiments several other distinct signals (27–29 kDa) were also 
observed which most likely correspond to either partially glyco-
sylated forms of GP3 or co-immunoprecipitation of other viral 
proteins i.e. GP2 and/or GP5.
Figure 1. Radioimmunoprecipitation with a rabbit monospecific GP3 
antiserum. A) Immunoprecipitation analysis of GP3 expressed in BHK-
21 cells (lane 2). Cells transfected with an empty vector (lane 1). B) 
MARC145 cells infected with PRRSV FL12 (lane 2). Mock-infected cells 
(lane 1). 
Figure 2. Radiolabeled viral suspension 
previously pelleted through a 30% sucrose 
cushion was layered on a continuous su-
crose gradient (20–60%) in TEN buffer. Vi-
rus titer and CPM/tube (determined in a 
scintillation counter) in the different frac-
tions was determined. Fractions 8–11 
which correspond to the peak infectivity 
and CPM counts were pooled, centrifuged 
and used for subsequent radioimmuno-
precipitation experiments. 
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GP3 is incorporated into PRRSV type II virion in a lesser amount than 
the major envelope proteins
In order to show that the GP3 was associated with the PRRSV 
type II virion, we utilized a two-step purification process of ex-
tracellular virus. The first round consisted of pelleting a clarified 
supernatant from PRRSV-infected MARC-145 cells containing ra-
diolabeled virions through a 30% sucrose cushion followed by a 
20–60% (W/V) sucrose gradient purification of 35S-labeled virus. 
Fractions were carefully collected from the top of the tube and 
used for titration, radioactivity counting and immunoprecipita-
tion experiments. Fractions containing the highest infectivity titers 
and radioactive counts (fraction nos. 8–11, Figure 2) were used for 
subsequent experiments.
Initially, total proteins derived from the pooled fractions con-
taining purified virus collected from a sucrose gradient were solu-
bilized in RIPA buffer and analyzed by reducing SDS-PAGE with-
out addition of antibody. We observed well defined bands with 
molecular weights corresponding to those reported for the major 
PRRSV structural proteins (Figure 3A). On the other hand, a small 
amount of a protein with a molecular weight of approximately 
42–45 kDa was also clearly observed in the lysate containing vi-
rion proteins.
In order to confirm the identity of the above-mentioned 42–
45 kDa protein, the pooled fractions containing purified virions 
were immunoprecipitated by incubation with anti-GP3 antibody 
and with a pool of a polyclonal antibody anti-GP5 and a monoclo-
nal antibody to M protein (generated in our laboratory against a 
synthetic peptide corresponding to a highly immunogenic linear 
epitope of M protein). However, due to the small amount of 42–
45 kDa protein visualized in the gel (Figure 3A), we used the ma-
jority of the lysate (70%) for immunoprecipitation with anti-GP3 
antibody, 20% of the lysate with an anti-GP5 and anti-M antibody 
and the remaining 10% of lysate used for loading as total protein 
(Figure 3B). Using this strategy, a specific band corresponding to 
GP3 was detected in pooled gradient fractions containing purified 
virions by RIP with anti-GP3 antiserum (Figure 3B, lane 2). In ad-
dition, a faint band, most likely corresponding to GP2 and/or GP5 
(27–29 kDa), was also co-precipitated by the anti-GP3 antibody.
Further evidence of the presence of GP3 at the level of PRRSV 
FL12 envelope was obtained by immunogold staining of the enve-
lope of purified virus present in the supernatant of infected cells 
with anti-GP3 antiserum (Figure 4). Purified virus was incubated 
with either pre-immune rabbit serum (Figure 4, panels A and B; as 
a negative control), anti-GP3 monospecific rabbit antiserum (Fig-
ure 4, panels C to G) and anti-PRRSV rabbit polyclonal antibody 
(Figure 4, panels H to J; as a positive control) followed by an anti-
rabbit IgG conjugated with gold particles. No staining was ob-
served when purified virions were incubated with a PRRSV neg-
ative serum whereas a strong reactivity was observed in virions 
incubated with a polyclonal antibody against GP5 as shown by 
the number of gold particles surrounding the virus envelope (Fig-
ure 4, panels H to J). On the other hand, the number of gold par-
ticles that were found associated with virions was clearly reduced 
when incubated with the anti-GP3 monospecific antiserum (Fig-
ure 4, panels C to G).
Discussion
In the present study, we confirmed the structural nature of GP3 in 
a North American strain of PRRSV (vFL12). PRRSV vFL12 is re-
covered from MARC-145 cells transfected with an infectious full-
length cDNA clone of PRRSV which has been extensively used 
in our laboratories (Ansari et al., 2006; de Lima et al., 2006, 2008; 
Kwon et al., 2006, 2008; Truong et al., 2004). In previous studies, 
GP3 of PRRSV has been shown to be incorporated into virions of 
European-type strains (van Nieuwstadt et al., 1996), however such 
Figure 3. A) Total protein derived from purified virus collected from a 
sucrose gradient (fractions 8–11) were solubilized in RIPA buffer and an-
alyzed by reducing SDS-PAGE (12% gel). B) Radiolabeled and purified 
virions were subjected to immunoprecipitation with GP3 monospecific 
antiserum (lane 2 — 70% of the lysate) or with a polyclonal antibody 
anti-GP5 and a monoclonal antibody to M protein (lane 3 — 20% of the 
lysate). 10% of the lysate was loaded onto lane 1. Immunoprecipitates 
were analyzed by reducing SDS-PAGE (12% gel). Position of the size 
markers are indicated in the left and positions of the PRRSV envelope 
proteins in the right side of the fluorograms. (*) Unidentified protein. 
Figure 4. Immunogold labeling of purified PRRSV particles with different antibodies. Purified virus was incubated with either pre-immune rabbit se-
rum (A and B; negative control), anti-GP3 monospecific rabbit antiserum (C to G) or, anti-PRRSV rabbit polyclonal antibody (H to J) followed by an 
anti-rabbit IgG conjugated with gold particles. Black bars shown correspond to 100 nm. 
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occurrence in PRRSV type II strains has been questioned by some 
publications (Gonin et al., 1998; Mardassi et al., 1998). Since then, 
the notion that PRRSV type II virions lacked GP3 prevailed.
In our study, RIP experiments confirmed the specificity of the 
anti-GP3 monospecific antiserum as measured by its reactivity 
with ORF3 protein either expressed by plasmid-transfected BHK-
21 cells or by PRRSV FL12-infected MARC-145 cells. Likewise, the 
GP3 was also detected by indirect immunofluorescence assay in 
the cytoplasm of methanol/acetone-fixed PRRSV-infected MARC-
145 cells using the antiserum as a primary antibody (data not 
shown). These findings unequivocally demonstrated the ability of 
the anti-GP3 antibody to recognize the ORF3 protein derived from 
the North American strain of PRRSV (FL12).
In order to demonstrate that association of the GP3 with the 
PRRSV type II virion, we used a purified preparation of 35S-labeled 
virus from the supernatant of infected MARC-145 cells. By using a 
scintillation counter, we observed a peak of radioactivity which cor-
responded to the fractions 8–11 collected from the sucrose gradi-
ent. Interestingly, viral titration of all fractions revealed the high-
est infectious titers in these fractions, thus confirming the presence 
of highly purified virions. Pooled fractions were directly analyzed 
by SDS-PAGE or subjected to RIP experiments using GP3 antibody. 
From these experiments, we concluded that the GP3 was less abun-
dant in purified virions than other known structural proteins such 
as GP5 and M (Figure 3). The appearance of GP5 as a broad smear 
is consistent with its incorporation into virions as a mature glyco-
protein with heterogeneous glycan moieties. The co-precipitation 
of the M protein in these experiments appears to be an inconsistent 
event and could possibly be related to the experimental conditions 
or due to some interaction between the M and GP3 protein. This 
type of unexpected co-precipitations amongst PRRSV proteins were 
also reported by Wu et al. (2005), who described some interaction 
occurring between N and 2b proteins.
The amount of GP3 incorporated into PRRSV type II virions is 
clearly lower when compared to the three major structural proteins 
N, M and GP5. It could be speculated that only a small fraction of 
the protein is incorporated into virions while other fraction(s) is 
(are) released into the culture medium. A comparison of the stain-
ing intensities suggests that the well-known major structural pro-
teins such as M and GP5 predominate in the virion, while GP3 
would be incorporated in significantly lower amounts. Thus, in or-
der to clearly visualize the GP3, a large amount of the lysate con-
taining purified virions was required whereas a large amount of 
GP5 was precipitated by the anti-GP5 polyclonal antibody in a frac-
tion of just a smaller percentage of the lysate. Similarly, analyses of 
the structural nature of GP3 and GP4 of Lelystad virus required a 
large amount of virus to visualize these proteins by immunostain-
ing on the nitrocellulose strips (van Nieuwstadt et al., 1996). Ac-
cording to this data, we demonstrated that a higher amount of ly-
sate derived from purified virus is necessary to visualize GP3 than 
the amount required to detect the major envelope proteins like GP5 
or M protein. This circumstance may, at least partially, explain the 
unsuccessful detection of ORF3 protein incorporated into virions in 
a previous study reporting that GP3 from a North American strain 
of PRRSV would not be part of the virion structure (Gonin et al., 
1998). Our results are also consistent with the detection of a much 
fainter band corresponding to the ORF 2b protein when compared 
to the amounts detected for GP5, M or N protein (Wu et al., 2001). 
Collectively, this data indicates that the 42–45 kDa protein is an in-
tegral but minor structural component of the PRRSV type II virion. 
Immunogold staining of purified virus present in the supernatant of 
infected cells with anti-GP3 antiserum provided further evidence of 
the presence of GP3 at the level of PRRSV FL12 envelope (Figure 4). 
While no staining was observed in purified virions incubated with a 
PRRSV negative serum, a strong reactivity was observed in virions 
incubated with an anti-PRRSV polyclonal antibody as shown by the 
number of gold particles surrounding the virus envelope (Figure 4, 
panels H to J). On the other hand, the number of gold particles that 
were found associated with virions was clearly reduced when incu-
bated with the anti-GP3 monospecific antiserum (Figure 4, panels C 
to G). This finding might be explained by the small amount of GP3 
incorporated into PRRSV virions.
The structural role for GP3 was suggested by recent findings re-
porting the ability of the PRRSV GP3 to induce neutralizing anti-
bodies either alone or in combination with GP4 and GP5 (Jiang et 
al., 2008). In addition, Cancel-Tirado et al. (2004) have demonstrated 
that a monoclonal antibody to Gp3 was associated with inhibition 
of PRRSV replication in porcine alveolar macrophages, thus pro-
viding further evidence for a possible presence of neutralizing epit-
opes in GP3. Recently the same laboratory has provided additional 
evidence, by chimeric reverse genetics studies of PRRSV US type 
II, that ORF3 contributes to the induction of neutralizing activity in 
serums, together with ORF5 and 6 (Kim and Yoon, 2008). In addi-
tion, partial protective immunity against PRRSV challenge was re-
ported in pregnant sows immunized with a recombinant baculovi-
rus expressing ORF3 from a Spanish strain of PRRS as measured by 
the number of piglets born alive and healthy at the time of weaning 
(Plana Duran et al., 1997). Pigs immunized with recombinant fowl-
pox expressing GP3/GP5 developed a specific immune response 
against the PRRSV proteins and most importantly, a degree of pro-
tection was also conferred against challenge with a pathogenic 
strain of PRRSV (Shen et al., 2007). Furthermore, it has also been re-
ported that ORF3 encodes a structural protein of Equine Arteritis 
virus (EAV). An additional study showed that the minor envelope 
glycoproteins GP2b, GP3, and GP4 of EAV form a heterotrimeric 
complex providing further evidence that the GP3 homologous pro-
tein of EAV is structural (Wieringa et al., 2004). Considering the ho-
mology among arteriviruses, other studies have indicated that all 
seven structural proteins of EAV are required for the production 
of infectious progeny virus (Molenkamp et al., 2000; Snijder et al., 
1999). Similar observations were also reported for PRRSV LV strain. 
Some authors (Wissink et al., 2005) have shown that all of PRRSV 
minor proteins interact with each other and they are assembled into 
virions as a multimeric complex, thus being essential for virus in-
fectivity. Overall, this set of data substantiates our observations in-
dicating that GP3 is a minor structural component of the PRRSV 
type II virions.
Materials and methods
Virus, cells and antibodies
FL12 strain is the PRRSV virus recovered from MARC-145 cells 
transfected with RNA transcripts produced in vitro from the full-
length infectious cDNA clone (vFL12) derived from PRRSV NVSL 
97-7895 type II strain (GenBank accession no. AY545985) (Truong 
et al., 2004). MARC-145 cells (Kim et al., 1993) were propagated in 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 5–10% 
fetal bovine serum (FBS) and antibiotics (100 U/ml of penicillin, 
20 μg/ml of streptomycin, and 20 μg/ml of kanamycin) and were 
used for viral multiplication and titration and for viral protein ex-
pression. The BHK-21 cells were maintained in MEM contain-
ing 5% fetal bovine serum (FBS) and antibiotics and used for tran-
sient expression of GP3. Indirect immunofluorescence assays (IFA) 
were performed as previously described (Kwon et al., 2006) using 
PRRSV N protein-specific monoclonal antibodies (MAbs): SDOW17 
(National Veterinary Services Laboratories – NVSL, Ames, IA) and 
SR30 [kindly provided by Dr. Eric Nelson (South Dakota State Uni-
versity, SD, USA)]. The secondary antibody used in both cases con-
sisted of a goat antimouse IgG antibody (Alexa Fluor – 488, Molecu-
lar Probes, Eugene, OR). For RIP experiments we used an anti-GP5 
polyclonal antibody (kindly provided by Dr Carl Gagnon, Univer-
sity of Montreal) and an anti-M monoclonal antibody raised against 
a synthetic peptide corresponding to a highly immunogenic B-cell 
linear epitope of M protein (de Lima et al., 2006) and previously 
characterized in our lab (data not shown).
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Selection and peptide synthesis
Based on previous studies in our laboratory (de Lima et al., 2006) 
we selected two highly immunogenic 15-mer peptides based on 
the glycoprotein 3 (GP3) amino acid sequence of a North Ameri-
can strain of PRRSV (NVSL 97-7895). The peptides were synthe-
sized and conjugated to a carrier protein (KLH) either by adding 
a cysteine residue or via activated EDC chemistry to its N-termi-
nal region. The amino acid residues of the selected peptides were 
Q61AAAEVYEPGRSLWC75 (cysteine originally found within the 
amino acid sequence of GP3) and S83EDDHDDLGFMVPG96C 
(cysteine residue added in order to facilitate its conjugation with 
KLH). These peptides were selected for the antiserum prepara-
tion based on their observed antigenicity and immunodominance 
in vivo (de Lima et al., 2006). While no definitive knowledge ex-
ists about the topology of PRRSV GP3, we would anticipate, based 
on previous knowledge of other multi-glycosylated viral envelope 
proteins, that these peptides are likely located in the ectodomain 
of PRRSV GP3.
Production of anti-GP3 monospecific rabbit antiserum
Two rabbits were used for this immunization; each receiving both 
KLH-conjugated peptides emulsified in complete (once, first shot) 
and incomplete (several ensuing and successive shots) Freund’s 
adjuvant. Animals were co-immunized (solution containing both 
peptides) at days 0, 14, 28, 42, 56 and 70. Bleedings were per-
formed on days 49, 63 and 77 post immunization and serum sam-
ples tested for the presence of anti-GP3 antibodies. Specific anti-
GP3 monospecific antiserum was collected at 77 days after first 
injection, characterized and used in all experiments.
Expression of GP3 in BHK-21 cells
For transient expression of GP3, the BHK-21 cells were plated 
in six well plates at 80% confluency. The following day the cells 
were washed with PBS and infected with recombinant vaccinia vi-
rus (VTF7-3) at a MOI of 3.0. Forty-five minutes after inoculation 
of the cultures, the cells were washed with PBS again and DNA-
Lipofectamine complex (2.0 μg of plasmid DNA: 5.0 μl of Lipo-
fectamine) was added to cells according to manufacturer’s proto-
col. The supernatant was replaced with complete growth medium 
after 4 h post-transfection. At 16 h post-transfection, the cells were 
washed with PBS and incubated with Methionine- and Cysteine-
free DMEM media to induce starvation. After one hour, 50 μCi 
of S35 (Express Protein Labelling Mix, [35S], Perkin Elmer) was 
mixed with 600 μl of Cys-Met free media, added onto cells and 
further incubated for 4 h. Immunoprecipitation was performed as 
described below.
Viral infection and metabolic labeling
Viral proteins derived from MARC-145 cells infected with PRRSV 
FL12 strain and extracellular virions were labeled as follows: for 
labeling of viral expressed intracellular GP3, the MARC-145 cells 
in six well plates were infected with PRRSV FL12 strain at a M.O.I. 
of approximately 1. At 18 h post infection (pi), cells were washed 
twice with PBS and subjected to starvation in methionine/cys-
teine-free DMEM for one hour. The starved cells were radiola-
beled with 0.6 ml of methionine/cysteine-free DMEM containing 
100 μCi of S35 (Express Protein Labelling Mix, [35S], Perkin Elmer) 
for 4 h and RIP was performed as described below. For radiolabel-
ing of extracellular virions, confluent monolayers of MARC-145 
cells in 100 mm plates were infected with PRRSV FL12 strain and, 
after 18 h, the infected cells were labeled with 6.0 ml of 100 μCi of 
l-[35S] methionine/ml. In this case the final medium was composed 
of 90% of Cys-Met-free medium and 10% of complete growth me-
dium. Virus particles were labeled overnight and the supernatant 
was collected and clarified by low speed centrifugation. Radiola-
beled PRRSV proteins and extracellular virus were used in subse-
quent immunoprecipitation experiments.
Virus purification
Above radiolabeled PRRSV virions were subjected to two rounds 
of purification. The clarified supernatant from PRRSV FL12-in-
fected MARC 145 cells containing radiolabeled virus was first 
pelleted through a 30% sucrose cushion and then submitted to 
a 20–60% (W/V) sucrose gradient overnight at 4 °C (100,000 g). 
Fractions were carefully collected from the top of the tube and 
used for titration, radioactivity counting and immunoprecipita-
tion experiments.
Radioimmunoprecipitation and SDS-PAGE analysis
Immunoprecipitation experiments were performed with 1) BHK-
21 cells transfected with GP3 expressing plasmid vector, 2) ra-
diolabeled proteins derived from MARC-145 cells infected with 
PRRSV; and 3) radiolabeled extracellular virions as described else-
where (Ansari et al., 2006). Fractions with the highest infectivity 
and CPM counting were pooled and used for subsequent RIP ex-
periments. Briefly, radiolabeled purified virus or cell extracts were 
resuspended in RIPA buffer (10 mM Tris–HCl pH 8.0, 150 mM 
NaCl, 1% Triton X-100, 0.1% SDS, 1% Sodium deoxycholate, and 
1× protease inhibitor). The clarified supernatants were incubated 
with anti-GP3 polyclonal antibody or with a pool of anti-GP5 and 
anti-M antibodies (1:100 dilutions) for 16 h at 4 °C with shaking. 
Approximately 3.0 μg of constituted Protein A Sepharose (Protein 
A Sepharose™ CL-48, GE Health care Bio-science AB) was added 
per tube and further incubated at 4 °C for two hours. The immune 
complexes were centrifuged at 10,000 rpm for 30 s and washed 
with RIPA buffer three times with five minute incubation, each 
time keeping the samples in a rotator at 4 °C. Finally the immune 
complexes were resuspended in 2× sample buffer and boiled for 
five minutes. The samples were again centrifuged briefly and the 
supernatants were analyzed by SDS-12% PAGE gel. The gel was 
fixed with 10% acetic acid for 15 min, washed three times with dis-
tilled water, treated with 0.5 M sodium salicylate for 30 min, dried 
and finally exposed to X-ray film at − 70 °C.
Immunogold staining
Briefly, after two rounds of low speed centrifugation, the clari-
fied supernatant of PRRSV-infected MARC-145 cells was pelleted 
through a 30% sucrose cushion by ultracentrifugation (25,000 rpm) 
for 2 h. Purified virus suspension was placed onto a formvar-car-
bon coated copper grid (duplicate grids were used for each exper-
iment) for approximately 1 min. Each grid was then placed on a 
drop of 5%BSA in PBS for 10 min. After, the samples were incu-
bated with an anti-GP3 monospecific rabbit antiserum for 30 min. 
Pre-immune rabbit serum was used as a negative control and anti-
PRRSV rabbit polyclonal hyperimmune serum (obtained by re-
peated immunizations of rabbits using supernatant and lysates 
of PRRSV-infected MARC-145 cells) as a positive control. All an-
tibodies were diluted in PBS with 5% BSA. The samples were then 
washed three times of five minutes each with PBS and incubated 
with an anti-rabbit IgG conjugated with 10 nm gold particles. Af-
ter another washing step, the samples were fixed in 3% glutaralde-
hyde in 0.1 M cacodylate buffer, negative-stained on a drop of 1% 
sodium silicotungstate and observed under electron microscopy.
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